Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (480)	5/21/2001 11:01:56 AM
From: tuck	Respond to of 2243

nigel, Don't have the definitive answer, but from hearing Dr. Santi talk at the CIBC conference, I'd say in general their strategy is to design their compounds to avoid stepping on other people's patents. There's been plenty of work on polyketides by other companies -- mostly pharmas -- so that is an issue. In this case, if BMS & Pharmacia synthesize it in inferior ways, perhaps the Sloan-Kettering technology could be licensed to them and others. >>time for a thread?<< Why not? I'm getting more casual about thread creation now that I've done it few times. Subject 51226 Cheers, Tuck